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Introduction: Patients undergoing on-pump cardiac surgery are at an increased risk of acute kidney injury.
QPI-1002, a small interfering ribonucleic acid, is under clinical development for the prevention of acute
kidney injury. The safety, tolerability, and pharmacokinetics of QPI-1002 was evaluated in this ﬁrst-in-man,
Phase 1 study of a small, interfering ribonucleic acid in patients at risk of acute kidney injury after on-pump
cardiac surgery.
Methods: In this phase 1 randomized, placebo-controlled dose-escalation study, a single i.v. dose of
QPI-1002 was administered in subjects undergoing on-pump cardiac surgery. Subjects received placebo
(n ¼ 4), or QPI-1002 in increasing doses of 0.5 mg/kg (n ¼ 3), 1.5 mg/kg (n ¼ 3), 5 mg/kg (n ¼ 3), and
10 mg/kg (n ¼ 3).
Results: A total of 16 subjects were enrolled in the study. The average maximum concentration and area
under the curve from the time of dosing to the last measurable concentration of QPI-1002 were generally
dose proportional, indicating that exposure increased with increasing dose. The average mean resi-
dence time (mean residence time to the last measurable concentration) was 10 to 13 minutes in all 4
drug-dosing cohorts. Adverse events occurred at a similar rate in all study groups. Of the total 109
reported adverse events, the events were distributed as 26 in the placebo group and 21, 19, 24, and 19 in
the QPI-1002 0.5, 1.5, 5.0, and 10.0 mg/kg groups, respectively. Eight of the 16 subjects experienced at
least 1 serious adverse event: 4 (100%) in the placebo group and 4 (33.3%) in the combined QPI-1002
cohorts.
Discussion: QPI-1002 was rapidly eliminated from plasma. QPI-1002 was safe and well tolerated across all
dose groups. Overall, no dose-limiting toxicities or safety signals were observed in the study. Further
development of QPI-1002 for prophylaxis of acute kidney injury is warranted.
Kidney Int Rep (2017) 2, 836–843; http://dx.doi.org/10.1016/j.ekir.2017.03.016
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A cute kidney injury (AKI) is a clinical syndromecharacterized by deterioration of renal function
that rapidly develops over hours to days. AKI com-
plicates a signiﬁcant proportion of hospital admissions
and is associated with an increased risk of chronic
kidney disease, major adverse cardiovascular events,
increased length of hospital stay, and additional health
care costs and mortality.1–3 Despite recent advances in
surgical techniques, the incidence of AKI remains high,
ranging from 33% to 55%.3
Current attempts to treat AKI remain largely sup-
portive, including the adjustment of medications,
appropriate nutritional support, correcting volume
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status, electrolyte imbalance, and acidosis,4 with or
without renal replacement therapy. At present, there
are no approved therapeutic agents available for the
prevention or treatment of AKI.
QPI-1002 (active ingredient: I5NP), a small, inter-
fering ribonucleic acid, is a synthetic, nuclease-
resistant, double-stranded RNA oligonucleotide
designed to temporarily inhibit the expression of the
proapoptotic gene p53 via activation of the RNA
interference pathway. The rat analogue of QPI-1002,
QM5, was shown to temporarily (<24 hours) sup-
press p53 protein-mediated apoptosis resulting from
ischemia-reperfusion injury (IRI).5 Inhibition of p53 in
several preclinical models of ischemia-reperfusion
injury demonstrated improved renal function post-
injury and improved histology.5 Small, interfering
RNA inhibition of p53 may work by providing addi-
tional time during which nonlethal injury to renal
tubular epithelial cells can be repaired before initiation
of apoptosis.6
The objective of this study was to evaluate the
safety, tolerability, and pharmacokinetics of QPI-1002
in this ﬁrst in human study in patients at risk of the
development of AKI while undergoing on-pump car-
diac surgery.
MATERIALS AND METHODS
QRK-002 was a phase 1, double-blind randomized,
placebo-controlled, dose-escalation study to evaluate
the safety and tolerability of a single i.v. bolus
injection of QPI-1002 to subjects scheduled to
undergo nonemergent, on-pump cardiac surgery at 6
centers globally. Patients were eligible if they were
21 to 85 years of age and up-to-date on screening
negative for cancer. Patients were excluded if their
postoperative Cleveland Clinic Foundation AKI
cumulative risk score was >8, they had received an
organ transplant, they were receiving immunosup-
pressive therapy, or they were women of child-
bearing potential.
The randomization was performed manually via a
centralized randomization system by unblinded Quark
personnel, per the QRK.002 Pharmacy Manual and
Patient Enrollment Guidelines, using the enrollment
form. In each QPI-1002 dosing cohort, the ﬁrst subject
was dosed as single, followed by double-blind,
placebo-controlled enrollment.
For each dose level, patients were allocated 3:1 to
receive a single i.v. bolus injection of QPI-1002 in doses
of 0.5, 1.5, 5.0, or 10.0 mg/kg or placebo (isotonic sa-
line) at 4  0.5 hours after discontinuation of cardio-
pulmonary bypass. The study protocol and informed
consent were reviewed and approved by institutional
review board or an independent ethics committee at
each site. The study was conducted in accordance with
the International Conference on Harmonization guid-
ance on Good Clinical Practice based on the Declaration
of Helsinki.
Pharmacokinetic plasma samples were collected just
before administration of the study drug (QPI-1002 or
placebo) and at 5, 15, and 30 minutes and 1, 2, 4, 8, and
24 hours post-dose. In addition to drug concentrations,
these samples were also analyzed for complement acti-
vation products (Bb, C3a, C4a, and C5a) to monitor for
the development of this previously described
class effect, reported for the related, but structurally
modiﬁed, phosphorothioate-substituted single-stranded
oligodeoxyribonucleotides.7,8 Baseline samples for
complement activation were taken before surgery.
Blood samples drawn into commercially available
K2-ethylenediamine tetraacetic acid–containing Vacu-
tainer tubes (Becton, Dickinson and Company, Franklin
Lakes, NJ) and were cold-centrifuged within 30 minutes
of phlebotomy, and the plasma was frozen at 70 C
pending shipment on dry ice to a central laboratory
(National Jewish Laboratory, Denver CO) for comple-
ment activation analyses and to Charles River Labora-
tories (Senneville, Quebec, Canada) for determination of
QPI-1002 (I5NP) concentrations.
Additional blood and urine samples were collected at
screening and postoperatively for routine determina-
tion of serum chemistry and hematology analytes,
indices of coagulation, and measures of renal (blood
urea nitrogen, serum creatinine), hepatic (aspartate
transaminase, alanine transaminase, alkaline phospha-
tase, and total bilirubin), and pancreatic (serum
amylase and lipase) function.
The QPI-1002 pharmacokinetic proﬁle for each
subject was evaluated by noncompartmental analysis
of I5NP plasma data using commercially available
computer software (WinNonlin Professional, version
5.3, Pharsight Corp., Mountain View, CA). Values
below the limit of quantitation were treated as
“missing.” The area under the QPI-1002 plasma con-
centration versus time curve from time zero to the last
quantiﬁable plasma concentration (AUClast) was
calculated using the linear trapezoidal method (linear
interpolation). Other values determined, where
possible, included maximum concentration (Cmax),
clearance (Cl), elimination half-life (T1/2), Vss, AUClast
extrapolated to inﬁnite time (AUC0-N), and the mean
residence time over the interval from time zero to the
last quantiﬁable time point mean residence time
(MRTlast).
Treatment emergent adverse events were deﬁned
as any adverse events occurring at any time from
study drug administration through day 7, based on
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the relatively short residence time of QPI-1002 in
plasma and proximal tubular epithelium.5 All
adverse events and serious adverse events were
reported through study day 30. Subjects were con-
tacted by telephone at 6 and 12 months to assess
medically signiﬁcant adverse events, including
death, need for renal replacement therapy, and
malignancy. Therapeutic efﬁcacy was not assessed in
this study.
There were no formal statistical tests of hypotheses.
A safety analysis was performed including all subjects
who were randomized to a study arm and had received
either the study drug or placebo and analyzed ac-
cording to the treatment that the subject actually
received.
Summary statistics including number of subjects (n),
mean, SD, median, minimum, and maximum were
presented for continuous variables. Categorical vari-
ables were summarized using counts and percentages.
RESULTS
A total of 16 subjects were enrolled in the study
(Supplementary Figures S1 and S2; QRK 002
ClinicalTrials.gov number, NCT00554359). The study
was initiated in October 2007, and the last subject was
enrolled in October 2009. The baseline and
demographic characteristics of the randomized subjects
are summarized in Table 1. The mean  SD age was
61.5  10 and 63  20 years for the QPI-1002–treated
and placebo-treated patients, respectively. Insulin-
dependent diabetes mellitus was present in 1 placebo-
treated and 5 QPI-1002–treated subjects (25.0% and
41.7%), respectively. A history of congestive heart
failure was present in 4 subjects treated with QPI-1002
and none in the placebo group.
Of the 16 participating subjects, 15 underwent cor-
onary artery bypass graft involving $1 coronary
arteries (n ¼ 6), valve replacement or repair (n ¼ 7), or
both (n ¼ 2). The remaining subject was scheduled for
aortic valve replacement, but additional procedures
were deemed necessary during surgery including
surgical repair of a dilated aortic root and a portion of
the ascending aorta. The mean preoperative Cleveland
Clinic Foundation risk scores,9 determined to assess the
level of risk for the development of postsurgical AKI
requiring acute dialysis, was 2.8 (on a scale of 0 to 13)
in both placebo- and QPI-1002–treated subjects;
among the QPI-1002–treated subjects, mean scores
ranged from 2.3 in the 10-mg/kg dose group to 3.7 in
the 5-mg/kg dose group (Table 1).
Baseline mean serum creatinine concentrations
ranged from 0.84 (10 mg/kg) to 1.26 (5 mg/kg) mg/dl.
Post-dosing, mean serum creatinine remained stable
Table 1. Patient demographics and baseline characteristics
Patient demographics/baseline
characteristics
Treatment groups
Placebo
(n [ 4)
QPI-1002
All
(n [ 16)
0.5 mg/kg
(n [ 3)
1.5 mg/kg
(n [ 3)
5.0 mg/kg
(v [ 3)
10 mg/kg
(n [ 3)
(Pooled)
(n [ 12)
Sex, n (%)
Male 3 (75) 2 (66.7) 3 (100) 2 (66.7) 3 (100) 10 (83.3) 13 (81.3)
Race, n (%)
White 3 (75) 1 (33.3) 3 (100) 3 (100) 3 (100) 10 (83.3) 13 (81.3)
Age (yr)
Mean 63.0 65.0 54.3 72.0 54.7 61.5 61.9
SD 20.61 8.72 14.19 4.36 0.58 10.68 13.00
BMI (kg/m2)
Mean 28.2 36.0 28.4 34.7 38.7 34.4 32.9
SD 4.46 8.91 2.07 5.92 7.00 6.80 6.76
Type of surgery
Valve only 2 (50) 1 (33.3) 3 (100) 1 (33.3) 0 (0) 5 (41.7) 7 (43.8)
CABG and valve 0 (0) 0 (0) 0 (0) 1 (33.3) 1 (33.3) 2 (16.7) 2 (12.5)
Other cardiac surgery 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0) 1 (8.3) 1 (6.3)
Preoperative serum creatinine (mg/dl)
<1.2 2 (50) 2 (66.7) 2 (66.7) 1 (33.3) 3 (100) 8 (66.7) 10 (62.5)
1.2–2.1 2 (50) 1 (33.3) 1 (33.3) 2 (66.7) 0 (0) 4 (33.3) 6 (37.5)
CCF score
Mean 2.8 3.0 2.3 3.7 2.3 2.8 2.8
SD 0.50 2.65 2.31 3.06 2.31 2.29 1.97
BMI, body mass index; CABG, coronary artery bypass graft; CCF, Cleveland Clinic Foundation.
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through day 7/hospital discharge in all but the 5-mg/kg
dose QPI-1002 group, in which the mean serum creat-
inine increased from 1.16 mg/dl at baseline to peak at
1.70 mg/dl on day 2, and progressively decreased to-
ward baseline (1.26 mg/dl) by day 30. This was deemed
attributable to the increased serum creatinine observed
in 1 patient with underlying chronic kidney disease.
The change in serum creatinine over time by treatment
group is presented in Figure 1.
Overall, no differences were observed for plasma
thromboplastin, activated partial thromboplastin time,
or international normalized ratio between treatment
groups at any time before or during the ﬁrst 7 days
after surgery and study drug administration.
The mean blood concentrations of the activated
complement components C3a, C4a, C5a, and Bb are
presented for placebo- and QPI-1002–treated patients
in Figure 2. The mean blood concentrations reﬂecting
classic complement pathway activation (C’3a, C’4a,
and C’5a) remained stable across all QPI-1002 and
placebo groups. Unlike the classic pathway factors,
mean postoperative, predose levels of alternate
pathway activated factor B (Bb) increased by 5.9- to
8.5-fold compared with baseline (screening) levels in
all groups, consistent with the previously described
impact of on-pump bypass surgery.1 In all patients,
Bb levels decreased at variable rates thereafter
(Figure 2). No differences in classic or alternate
pathway complement activation were observed
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Figure 2. (a) Mean C3a levels by treatment group before and after on-pump cardiac surgery. (b) Mean C4a levels by treatment group before and
after on-pump cardiac surgery. (c) Mean C5a levels by treatment group before and after on-pump cardiac surgery. (d) Mean Bb levels by
treatment group before and after on-pump cardiac surgery.
Figure 1. Change in mean serum creatinine concentration over time
by treatment group and study visit.
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between placebo- and QPI-1002–treated patients at
any dose level.
I5NP (active ingredient) was detected in all patients
who received QPI-1002 but was not detected in any
patient who received placebo. In Cohort 1, I5NP was
quantiﬁed in plasma up to 4 hours. In Cohorts 2
through 4, I5NP was quantiﬁable up to 4 to 8 hours and
up to 24 hours in 1 patient in Cohort 4. Due to the lack
of plasma concentrations above the assay limit, phar-
macokinetic analysis could not be conducted in 1 of 3
patients in each of Cohorts 1 and 2. Therefore, phar-
macokinetic parameters were estimated for 10 patients.
AUC0-N was not reported for the majority of patients
due to the unacceptably large percentage of extrapo-
lation from AUClast.
Average QPI-1002 Cmax and AUClast values increased
with increasing dose from 7.64 to 261 mg/ml and from
2.33 to 85.6 mg$hr/ml, respectively, across the range of
studied doses (Table 2). The increase in both parame-
ters generally increased proportionally with increasing
dose, despite high interpatient variability and the small
number of observations. The average dose-normalized
Cmax values were 14.6, 8.30, 10.8, and 26.0 for Co-
horts 1 through 4, respectively. For patients in all 4
cohorts, QPI-1002 was rapidly cleared from plasma
with a mean residence time (MRTlast) of 10-13 minutes
(Figure 3). This is consistent with the rapid elimination
of I5NP and its analogues observed in nonhuman pri-
mates, in normal rats and in rats with impaired kidney
function (5/6 nephrectomy model).
Adverse Events
During the ﬁrst 30 post-operative days, a total of 109
AEs were reported among all 16 study participants.
The distribution of AEs was similar across all treatment
group: 26, 21, 19, 24, and 19 in the placebo and QPI-
1002 0.5, 1.5, 5, and 10 mg/kg cohorts, respectively
(Table 3); the majority (90 [83.5%]) were mild or
moderate (NCI CTC AE Grades 1 or 2) in severity. The
overall distribution of Grade 1 and 2 events was also
similar across cohorts: 22 (84.6%), 20 (95.2%), 13
(63.4%), 20 (83.4%) and 18 (85.3%), respectively. The
most frequent of these were hypotension, reported in 2
placebo and 5 QPI-1002 recipients overall (50% and
41.7%, respectively), pleural effusion in 1 (25%) and 5
(41.7%), respectively, and constipation in 0 and 4
(33.3%), respectively (Table 4). Overall, only 2 AEs
were investigator-assessed as “Possibly Related;”
both were for Grade 3 worsening anemia that devel-
oped during the perioperative period—one in a
placebo- and the other in a QPI-1002 (1.5 mg/kg)-
treated patient.
A total of 17 serious adverse events (SAEs) were
reported in 8 (4 placebo-treated [100%] and 4 QPI-
1002-treated [33.3%]) subjects through 180 days of
follow-up. Through study day 365, an additional 7
SAEs were reported in 4 (Placebo: 1; QPI-1002: 3)
subjects, none of which were investigator-assessed as
related or possibly related. Of these, only 1 episode of
atrial ﬁbrillation in the Placebo group and another 2
episodes of bradycardia in the QPI-1002 group, 1.5-
and 10- mg/kg treatment groups, respectively, were
reported for >1 patient. A single event of grade 3
prostate cancer was reported as an AE at study day 237
in a 70-year-old subject with a history of benign
Table 2. Mean (min-max) QPI-1002 plasma PK estimates
PK parameter
QPI-1002 dose (mg/kg)
0.5 1.5 5.0 10
n 2 2 3 3
Cmax (mg/ml) 7.64 (5.7–9.6) 12.4 (9.80–14.9) 54.0 (22.8–89.7) 261 (169–441)
AUClast (mg$hr/ml) 2.33 (1.81–2.85) 3.82 (3.01–4.62) 21.1 (15.1–31.4) 85.6 (63.6–129.4)
MRTlast (hr) 0.166 (0.152–0.180) 0.172 (0.164–0.179) 0.174 (0.141–0.210) 0.216 (0.184–0.244)
Tlast (hr) 4 (4–4) 6 (4–8) 8 (8–8) 13.4 (8–24)
Clast (ng/ml) 0.335 (0.320–0.349) 0.572 (0.250–0.894) 0.175 (0.167–0.192) 0.581 (0.136–1.28)
AUClast, area under the curve from the time of dosing to the last measurable concentration; Clast, concentration corresponding to Tlast; Cmax, maximum observed plasma concentration;
MRTlast, mean residence time to the last measurable concentration; Tlast, time of last measurable concentration.
Figure 3. Plasma concentrations of QPI-1002 after i.v. administration
of 0.5 mg/kg (Cohort 1), 1.5 mg/kg (Cohort 2), 5 mg/kg (Cohort 3), or
10 mg/kg (Cohort 4).
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prostatic hypertrophy treated with 5 mg/kg I5NP in
whom a locus of adenocarcinoma was identiﬁed in
prostate tissue resected for benign prostatic hypertro-
phy. The event was considered not related and had
resolved without sequelae at the time of study
completion. No dose-limiting toxicities were identiﬁed,
either per the prospectively deﬁned criteria speciﬁed in
the protocol or by the independent Data Safety Moni-
toring Board for this study. There were no deaths or
study discontinuations due to reported AEs.
DISCUSSION
We report the i.v. adminstration of QPI-1002 in a phase
I safety, tolerability, and pharmacokinetic study in
subjects undergoing on-pump cardiac surgery and at
risk of the development of AKI. We demonstrated that
single i.v. bolus injections of QPI-1002 were safe, well
tolerated, and without immediate reaction at any dose
in the range of 0.5 to 10.0 mg/kg when administered at
4 hours post–cardiopulmonary bypass. The drug was
rapidly eliminated from plasma, with an average mean
residence time (MRTlast) of 10 to 13 minutes in all 4
dosing cohorts. In preclinical models, the siRNAs were
shown to undergo rapid glomerular ﬁltration and
proximal tubular epithelial uptake.5 Thus, bolus i.v.
injection is an effective means of delivering a “naked”
siRNA to the proximal tubule, which is a key target of
IRI.
QPI-1002 is a siRNA targeting p53 mRNA and
designed to temporarily downregulate the expression
of p53 protein via the RNA interference (RNAi)
pathway. P53 plays a major role in ischemia reperfu-
sion–induced AKI and has emerged as the pivotal
regulator of apoptosis (i.e., programmed cell death).10–
14 QPI-1002 and other synthetic siRNAs are metabo-
lized by cellular endonucleases in a manner similar to
endogenously produced oligoribonucleotides.15 RNA
interference via QPI-1002 is expected to mitigate the
premature elimination of reversibly damaged proximal
tubular epithelial cells via programmed cell death,
without exacerbating the postischemic inﬂammatory
response; this is demonstrated by the fact that admin-
istration of murine double minute-2 antagonist, which
metabolizes p53 protein, suppresses inﬂammation
following AKI in p53 knockout mice in a p53-inde-
pendent manner.16–18
Although p53 is also involved in the longer term
process of immune surveillance, studies in wild-type
and p53 knockout mice have clearly shown that
transient p53 suppression, for periods of up to 7
days, was not associated with a long-term increase in
the risk of malignant transformation, so long as p53
activity was subsequently restored.19 No unexpected
malignancy was reported in any patient in this small
and short-duration trial. Overall, QPI-1002 is rapidly
eliminated via the kidneys and minimally distrib-
uted to other organs/tissues and has a duration of
action limited to w48 to 72 hours in preclinical
studies.5
Subjects treated with QPI-1002 had an AE proﬁle
similar to what was observed in the placebo group.
Overall, other than worsening anemia, no other
AEs were investigator-assessed as “possibly related” in
either group. Some structually altered oligodeoxyr-
ibonucleotides, those with phosphorothioate-
substituted backbones, were previously reported to
cause dose-dependent prolongation of coagulation
Table 4. Most frequently reported adverse events for QPI-1002
versus placebo-treated patients Through day 30
Event QPI-1002, n (%) Placebo, n (%)
Hypotension 5 (41.7) 2 (50.0)
Pleural effusion 5 (41.7) 1 (25.0)
Anemia 3 (25.0) 2 (50.0)
Constipation 4 (33.3) 0 (0.0)
Nausea 3 (25.0) 0 (0.0)
Leukocytosis 3 (25.0) 2 (50.0)
Elevated AST 3 (25.0) 1 (25.0)
Pulmonary edema 3 (25.0) 0 (0.0)
Peripheral edema 3 (25.0) 0 (0.0)
AST, aspartate transaminase.
Table 3. Counts of adverse events (through day 30) by dosing cohort
Through day 30
Placebo
n [ 4
QPI-1002
0.5 mg/kg
n [ 3
1.5 mg/kg
n [ 3
5.0 mg/kg
n [ 3
10.0 mg/kg
n [ 3
Pooled
n [ 16
No. of events 26 (100.0%) 21 (100.0%) 19 (100.0%) 24 (100.0%) 19 (100.0%) 109 (100.0%)
CTCAE severity grades
1 13 (50.0%) 12 (57.1%) 6 (31.6%) 7 (29.2%) 15 (78.9%) 53 (48.6%)
2 9 (34.6%) 8 (38.1%) 7 (36.8%) 13 (54.2%) 3 (15.8%) 40 (36.7%)
3 4 (15.4%) 1 (4.8%) 5 (26.3%) 4 (16.7%) 1 (5.3%) 15 (13.8%)
4 0 (0.0%) 0 (0.0%) 1 (5.3%) 0 (0.0%) 0 (0.0%) 1 (0.9%)
CTCAE, Common Terminology Criteria for Adverse Events.
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times (activated partial thromboplastin times greater
than prothrombin times) and/or exposure-dependent
complement activation (C’3a, C’5a, Bb).20 However, no
evidence of increased complement activation or coa-
gulopathy was observed with single-dose i.v. bolus
administration of QPI-1002 in this study.
In summary, we report results for a phase I, safety,
tolerability, and pharmacokinetics study of single-
dose, i.v. bolus administration of QPI-1002 in subjects
undergoing on-pump cardiac surgery who were at risk
of the development of AKI. This was the ﬁrst study
that involved the systemic administration of a siRNA in
human subjects. Our study has all the limitations of
small-sized randomized studies. We conclude that QPI-
1002, when administered as a single i.v. bolus injection
at 4 hours after discontinuation of cardiopulmonary
bypass, was well tolerated and was not associated with
unexpected or unfavorable AEs. Further study of QPI-
1002 is needed to assess its clinical efﬁcacy and addi-
tional safety for the prevention of AKI and its associ-
ated outcomes in patients undergoing cardiovascular
surgery.
At present, 2 studies are ongoing to assess the efﬁ-
cacy and additional safety of QPI-1002: prevention of
acute kidney injury following cardiac surgery
(NCT02610283 phase 2) and prevention and reduction
in severity of delayed graft function in recipients of an
older donor kidney transplant (NCT02610296 phase 3).
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